{
    "clinical_study": {
        "@rank": "52025", 
        "arm_group": {
            "arm_group_label": "Prazosin Hydrochloride", 
            "arm_group_type": "Experimental", 
            "description": "Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out whether short term treatment with a\n      antihypertensive medication prazosin, can influence the levels of a dopamine in the brain.\n      We will examine the levels of dopamine in the the brain using Positron Emission Tomography\n      (PET) and Magnetic Resonance Imaging (MRI). We hypothesize that there will be no significant\n      changes in dopamine levels in healthy individuals taking prazosin."
        }, 
        "brief_title": "The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The purpose of this study is to find out whether short term treatment with a\n      antihypertensive medication prazosin, can influence the levels of dopamine in the brain. We\n      will examine the levels of dopamine in the the brain using Positron Emission Tomography\n      (PET) and Magnetic Resonance Imaging (MRI). The study will involve three PET scans and one\n      MRI. One PET scan will be performed before the participants take prazosin for approximately\n      three weeks, and the last two PET scans will be performed after the prazosin medication\n      phase. We hypothesize that there will be no significant changes in dopamine levels in\n      healthy individuals taking prazosin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males and females of any ethnic origin between 19 and 45 years old\n\n        Exclusion Criteria:\n\n          -  Use of any illicit drugs in past 3 months prior to randomization and/or have a\n             current or past diagnosis of drug abuse/dependence (including alcohol)\n\n          -  Current or past DSM-IV diagnosis of any Axis I psychiatric disorder\n\n          -  Major psychiatric illness and/or substance dependence in first order relatives\n\n          -  Current active or past suicidal ideation\n\n          -  Baseline systolic blood pressure  outside the normal range\n\n          -  Current use of medications that could interact with prazosin (e.g. beta blockers,\n             phosphodiesterasetype 5 inhibitors, indomethacin, verapamil, modafinil, clonidine)\n\n          -  Current use or use during the previous month of medication that may affect the CNS at\n             the time of scanning (e.g. neuroleptics, bupropion)\n\n          -  Any significant abnormalities in baseline blood results (e.g. CBC, renal and hepatic\n             indicators) or ECG readings that would preclude the use of prazosin\n\n          -  Pregnancy, trying to become pregnant or breastfeeding\n\n          -  Presence of metal objects in the body (e.g. some artificial joints, bone pins,\n             surgical clips, skull plate, certain part of dental braces) or implanted electronic\n             devices (e.g. cardiac pacemaker, neurostimulator), that preclude safe MR scanning\n\n          -  Claustrophobia\n\n          -  Participation in any nuclear medicine procedures that, including the dose received\n             during participation in this study, will bring the total radiation dose over the\n             currently approved guideline of 20mSv in a 12-month period\n\n          -  Cardiovascular or cerebrovascular diseases\n\n          -  History of or current neurological illnesses including seizure disorders, migraine,\n             multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor\n\n          -  Abnormal body mass (defined as not within 20% of normal BMI\n\n          -  Learning disability, amnesia or other conditions that impede memory and attention"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999530", 
            "org_study_id": "224/2012"
        }, 
        "intervention": {
            "arm_group_label": "Prazosin Hydrochloride", 
            "description": "Gradual upward titration to 15mg/day for approximately three weeks.", 
            "intervention_name": "Prazosin Hydrochloride", 
            "intervention_type": "Drug", 
            "other_name": [
                "Teva-Prazosin", 
                "Prazosin", 
                "Minipress"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dopamine", 
                "Dopamine Agents", 
                "Prazosin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prazosin", 
            "dopamine", 
            "healthy", 
            "Positron Emission Tomography", 
            "PHNO", 
            "scan", 
            "effect"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching", 
            "url": "http://www.camh.net/research"
        }, 
        "location": {
            "contact": {
                "email": "shakira.mohammed@camh.ca", 
                "last_name": "Shakira Mohammed, H.BSc", 
                "phone": "416-535-8501", 
                "phone_ext": "30509"
            }, 
            "contact_backup": {
                "email": "thulasi.thiruchselvam@camh.ca", 
                "last_name": "Thulasi Thiruchselvam, H.BSc", 
                "phone": "416-535-8501", 
                "phone_ext": "6087"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5T 1R8"
                }, 
                "name": "Centre for Addiction and Mental Health"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Exploring the Effects of Prazosin on Basal Dopamine in Healthy Humans: A [11C]-(+)-PHNO PET Pilot Study", 
        "overall_official": {
            "affiliation": "Centre for Addiction and Mental Health", 
            "last_name": "Bernard Le Foll, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Outcome measure occurs before taking medication, after 3 weeks of medication, and after washout of about one week (+/- a few days)", 
            "measure": "Changes in [11C]-(+)-PHNO binding", 
            "safety_issue": "No", 
            "time_frame": "0, 3 weeks, 1 week washout"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999530"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre for Addiction and Mental Health", 
            "investigator_full_name": "Bernard Le Foll", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Centre for Addiction and Mental Health", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ontario Lung Association", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pfizer", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Centre for Addiction and Mental Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}